- Home
- ROC vs KZIA Comparison
ROC vs KZIA Comparison
Compare ROC & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROC | KZIA |
|---|---|---|
| Founded | 2015 | 1994 |
| Country | United States | Australia |
| Employees | 82 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.6M | 100.8M |
| IPO Year | N/A | 2002 |
Fundamental Metrics
Financial Performance| Metric | ROC | KZIA |
|---|---|---|
| Price | $5.12 | $13.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $9.00 | ★ $19.50 |
| AVG Volume (30 Days) | 66.3K | ★ 169.2K |
| Earning Date | 03-31-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.71 | $4.86 |
| 52 Week High | $7.80 | $17.40 |
Technical Indicators
Market Signals| Indicator | ROC | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 52.39 |
| Support Level | $4.42 | $5.44 |
| Resistance Level | $5.32 | $14.75 |
| Average True Range (ATR) | 0.60 | 1.04 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 62.61 | 46.92 |
Price Performance
Historical ComparisonAbout ROC Rank One Computing Corporation Common stock
Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.